research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
Search
for
Sort by
Research
810-840 / 1000+ results 
research Tribuloside Acts on the PDE/cAMP/PKA Pathway to Enhance Melanogenesis, Melanocyte Dendricity and Melanosome Transport
Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
research Hairy Tongue Associated With the Use of Baricitinib Therapy for Ophiasis Pattern Alopecia Areata
A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
research Clinical Guidelines of Ukrainian Hair Research Society: Diagnosis and Treatment of Alopecia Areata
The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.
research Effectiveness of Oral Tofacitinib Treatment on Patients With Moderate-to-Severe Alopecia Areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research Screening for Latent Infectious Disease in Patients with Alopecia Areata Before Initiating JAK Inhibitors Therapy: A Single-Center Real-World Retrospective Study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Effectiveness of Tofacitinib in Pre-Adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Review of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Treatment of Refractory Folliculitis Decalvans With the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research Beyond the Epidermal-Melanin-Unit: The Human Scalp Anagen Hair Bulb Is Home to Multiple Melanocyte Subpopulations of Variable Melanogenic Capacity
The human scalp hair bulb contains different types of melanocytes with varying abilities to produce melanin.
research Treatment Modalities for Lymphocytic and Neutrophilic Scarring Alopecia
Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
research An Update in the Management of Alopecia Areata
New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
research Androgenetic Alopecia: An Update
Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
research Beyond the Epidermal-Melanin-Unit: The Human Scalp Anagen Hair Bulb Is Home to Multiple Melanocyte Subpopulations of Variable Melanogenic Capacity
The human scalp has different types of pigment cells in hair follicles with varying abilities to produce pigment.
research An Overview of Alopecia Areata: Etiopathogenesis, Diagnosis, and Management
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research Pathogenetically Significant Risk Factors for Development of Androgenetic Alopecia
Inflammation in hair follicles is a key risk factor for developing common baldness.
research Identification of Distinct Immune Signatures and Chemokine Networks in Scalp Inflammatory Diseases
Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.
research Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
research Logic-Based Modeling and Drug Repurposing for the Prediction of Novel Therapeutic Targets and Combination Regimens Against E2F1-Driven Melanoma Progression
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
research Efficacy and Safety of Baricitinib in Managing Severe Alopecia Areata: A 6-Month Real-World Experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Overview Of Alopecia Areata For Managed Care And Payer Stakeholders In The United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Systemic Immunotherapies
Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.